INTRODUCTION
============

Treatment-resistant depression (TRD) is a chronic debilitating condition with profound sequelae. Only one-third of patients remit after receiving first-line therapy for major depressive disorder (MDD ([@bib41]), and approximately half of patients who do not respond to the first antidepressant therapy will not respond to a second agent ([@bib43]). Even after multiple interventions, approximately one-quarter of patients remain depressed, and the likelihood of response to antidepressants decreases with the number of failed treatment courses ([@bib33]). Furthermore, those who require multiple antidepressant interventions appear to be at significantly greater risk of subsequent relapse despite ongoing therapy ([@bib33]).

Increased morbidities, such as increased risk of substance abuse, greater social, and vocational impairment, higher suicide risk, and greater resource utilization, are all associated with TRD ([@bib28]). In contrast to depressed persons without TRD, patients with TRD are at least twice as likely to be hospitalized, are prescribed up to three times as many psychotropic medications, and have higher medical costs owing to polypharmacy ([@bib15]; [@bib18]).

Relapse in depression comes at high medical, social, and economic costs ([@bib40]; [@bib44]); and most clinicians strive to prevent patients with MDD from relapsing. Relapse rates in difficult-to-treat patients may be higher than a non-treatment-resistant population; STAR\*D analyses found that ∼25% of treatment-resistant patients who remitted on level 1 citalopram relapsed within 6--12 months of achieving remission ([@bib20]). The STAR\*D trial also found that those who required more treatment levels to achieve remission had higher relapse rates, potentially reflecting that the more difficult-to-treat populations are at an even greater risk of relapse ([@bib17]).

Numerous treatment strategies have been employed to manage TRD, including augmentation with lithium ([@bib8]) or second-generation antipsychotics (SGAs) ([@bib16]; [@bib21]; [@bib32]; [@bib45]), switching antidepressants ([@bib5]; [@bib33]), and combining antidepressants ([@bib9], [@bib10]; [@bib11]; [@bib24]; [@bib27]). Cumulative evidence supports SGA augmentation in most guidelines for partial or nonresponders in clinical practice ([@bib2]; [@bib4]; [@bib7]; [@bib22]).

Olanzapine/fluoxetine combination (OFC) is a combination of the antipsychotic, olanzapine, and the antidepressant, fluoxetine. The short-term effectiveness of OFC for TRD is supported by results from randomized, controlled, and acute-phase studies ([@bib14]; [@bib35], [@bib36]; [@bib39]; [@bib42]). In each study, OFC rapidly reduced depressive symptoms, with three of the studies showing significantly greater improvement than antidepressant monotherapy at study endpoint ([@bib14]; [@bib35]; [@bib39]). Additionally, in a 76-week, open-label study, OFC showed rapid and sustained improvement of depressive symptoms in patients with MDD, including patients with TRD ([@bib13]).

The effectiveness of OFC in this patient population beyond 8 weeks has not been established in controlled clinical studies. Because it is generally accepted that TRD is a chronic illness requiring chronic treatment, physicians should periodically reexamine the need for continued OFC treatment. However, the question of how long a patient should be treated or maintained with OFC benefit remains. For instance, once the patient achieves a level of clinical stabilization on OFC, can the antipsychotic then be removed? The following study compared time-to-relapse in patients stabilized on OFC who were then randomized to either continued OFC treatment or treatment with fluoxetine alone across a 27-week period of double-blind treatment.

MATERIALS AND METHODS
=====================

Patient Population
------------------

Eligible patients were men and women, inpatients or outpatients, aged 18--65 years diagnosed with single or recurrent unipolar MDD without psychotic features, defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) ([@bib1]) and confirmed by the Structured Clinical Interview for DSM (SCID)-I Clinical Version, including MDD specifiers in the Research Version of SCID-1 (diagnoses 296.31, 296.32, and 296). Patients were required to have a 17-item Hamilton Depression Scale score ⩾18 at visits 1 and 2. TRD, defined as failure to achieve a satisfactory antidepressant response to adequate and separate treatment courses (⩾6 weeks for each medication) of ⩾2 different antidepressants in the current MDD episode. Permitted antidepressant failures/treatments with equivalent doses considered appropriate for protocol subjects were provided. Patients previously resistant or nonresponsive to fluoxetine or OFC were excluded to ensure that patients who were known as nonresponders did not influence study results.

Patients with the following disorders or treatments were excluded: schizophrenia and related disorders, Bipolar Disorder I or II; diagnosis of substance dependence according to DSM-IV-TR criteria ⩽30 days before visit 1; Parkinson\'s disease or related disorders, postpartum depression, MDD with atypical features or with a seasonal pattern, or certain personality disorders (schizoid, schizotypal, antisocial, and borderline); psychotic symptoms 1 month before entering the study or current; current suicidal ideation per investigator\'s opinion; treatment with electroconvulsive therapy or vagus nerve stimulation within the current episode; treatment with clozapine or a monoamine oxidase inhibitor ⩽14 days before visit 1; or with remoxipride within 6 months prior to visit 2.

Study Design
------------

This was a multicenter, randomized, double-blind, active-comparator-controlled, parallel-group, phase 3 study conducted between July 2009 and March 2012 at multiple centers in Argentina, India, Mexico, Puerto Rico, Russia, South Africa, Turkey, and the United States. The study consisted of four study periods ([Figure 1a](#fig1){ref-type="fig"}). Patients entered a 3- to 14-day screening period (Study Period I (SPI)). Eligible patients continued to a 6- to 8-week, open-label, acute treatment period and were assessed weekly (Study Period II (SPII)). Patients who met the response criteria, defined as ⩾50% improvement from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) ([@bib26]) and a Clinical Global Impressions-Severity of Depression (CGI-S) ([@bib31]) score ⩽3, after ⩾6 weeks of treatment, were permitted to move into a 12-week open-label stabilization period (Study Period III (SPIII)); patients were discontinued from SPII if response criteria were not met by 8 weeks. During the 12-week stabilization period (SPIII), patients were assessed weekly and had to maintain ⩾50% improvement relative to baseline (visit 2) on MADRS and maintain CGI-S scores ⩽3 at all stabilization phase visits to be eligible for randomization to the double-blind, relapse-prevention period (Study Period IV (SPIV)); up to three excursions from these criteria were allowed, provided the excursions did not occur at consecutive visits nor at the last visit of the stabilization phase. Eligible stabilized patients were then randomly assigned in a 1:1 ratio to either receive fluoxetine only or continue receiving OFC during a 27-week, double-blind, relapse-prevention period (SPIV) in which they were assessed a total of nine times at weeks 21, 23, 25, 29, 33, 37, 41, 45, and 47 of the study. To minimize bias, investigators and patients were blinded to stabilization criteria during SPIII, timing of the start of the relapse-prevention phase with either OFC or fluoxetine, and criteria for continuation in SPIV.

During SPII and SPIII, to increase tolerability, patients were initiated at a 3/25 dose (SPII only) and then flexibly dosed thereafter using doses of 6/25, 12/25, 6/50, 12/50, and 18/50 mg/day (olanzapine/fluoxetine). A forced titration scheme was implemented whereby patients who had not met criteria for improvement, did not have potentially dose-related adverse events (AEs), and had not achieved the maximum dose of medication had their dosage increased.

During SPIV, all patients followed a fixed dosing regimen. Patients randomized to OFC continued the same dose received at the end of the open-label stabilization period. Patients randomized to fluoxetine maintained a fixed dose of fluoxetine consistent with their last OFC dose (25 or 50 mg). During the first week of SPIV, the fluoxetine-treated patients also continued to receive a gradually tapered concomitant dose of olanzapine to minimize inadvertent unblinding secondary to abrupt removal of a sedating agent. All patients in SPIV received the same number of capsules.

Study Measures
--------------

The primary efficacy assessment was to evaluate the long-term efficacy of OFC *vs* fluoxetine in the treatment of patients with TRD, as measured by the time-to-relapse during the double-blind period. Relapse was defined as meeting any of the following criteria: 50% increase in the MADRS score from randomization with concomitant CGI-S score increase to ⩾4; hospitalization for depression or suicidality; or discontinuation due to lack of efficacy or worsening of depression or suicidality. Secondary efficacy measures included assessment of rates of relapse and time-to-relapse for each of the three individual relapse criteria. Response, stabilization, and remission rates were also assessed. Response was defined as ⩾50% improvement from baseline on MADRS and a CGI-S score ⩽3, and remission was defined as a MADRS score ⩽8. Additional secondary assessments included the Sheehan Disability Scale ([@bib34]) and collection of resource utilization and hospitalization data.

Safety assessments included reports of spontaneous AEs collected at every visit, vital signs, laboratory analytes, and electrocardiograms. Suicide-related thoughts and behaviors were assessed using the Columbia Suicide Severity Rating Scale (C-SSRS) ([@bib29]), and emergence of mania was measured by incidence of treatment-emergent adverse events (TEAEs) possibly related to mania. Extrapyramidal symptoms (EPS) were assessed using the Barnes Akathisia Scale (BAS) ([@bib6]), Simpson--Angus Scale ([@bib37]), and the Abnormal Involuntary Movement Scale (AIMS) ([@bib30]).

Statistical Analyses
--------------------

Time-to-relapse was analyzed using the Kaplan--Meier survival estimation method, and log-rank test was used for treatment group comparison. For a more complete assessment of the magnitude of treatment effect on time-to-relapse, a *post hoc* Cox proportional hazards model was also applied to obtain a related hazard ratio. Differences in rates of relapse, response, and remission were tested using Cochran--Mantel--Haenszel tests adjusting for country. Paired *t*-tests or Wilcoxon tests were used for continuous variables within treatment groups. A mixed model for repeated measures was used for comparisons between treatment groups for continuous variables. Tests of safety measures between treatment groups were performed using Fisher\'s exact test. All tests were two-sided using a significance level of 0.05 with no adjustments for multiplicity. The test addressing the primary objective was confirmatory, whereas all others were suggestive.

RESULTS
=======

Patient disposition is summarized in [Figure 1b](#fig1){ref-type="fig"}.

Acute and Stabilization Phases (SPII and SPIII)
-----------------------------------------------

Of 892 patients who entered SPII, 237 (26.6%) discontinued; the most common reason for early discontinuation was 'response criteria not met\' (*N*=80 (9.0%)). Of 655 patients who entered SPIII, 211 (32.2%) discontinued, with the most common reason for early discontinuation being 'stabilization criteria not met\' (*N*=62 (9.5%); [Figure 1b](#fig1){ref-type="fig"}). Patient demographics and characteristics were similar between SPII and SPIII ([Table 1A](#tbl1A){ref-type="table"}).

### Efficacy

The mean MADRS total score of all patients entering SPII was 30.4 and the mean CGI-S score was 4.6. Patients at SPIII entry had a mean MADRS total score of 9.3 and a mean CGI-S score of 2.3 ([Table 1A](#tbl1A){ref-type="table"}).

### Safety

There were no deaths during SPII and SPIII; 13 (1.5%) and 9 (1.4%) patients, respectively, reported ⩾1 serious adverse event (SAE), whereas 44 (4.9%) and 28 (4.3%), respectively, discontinued owing to an AE. A total of 610 (68.4%) and 352 (53.7%) patients reported TEAEs during SPII and SPIII, respectively ([Table 2](#tbl2){ref-type="table"}). Nineteen (2.3%) and seven (1.1%) patients, respectively, reported treatment-emergent akathisia as defined by the BAS (global score \<2 at baseline and global score ⩾2 post baseline). Fourteen (1.7%) and 20 (3.1%) patients, respectively, reported treatment-emergent Parkinsonism as defined by the SAS (total score ⩽3 of items 1--10 at baseline and a total score \>3 of items 1--10 post baseline). No patients in SPII reported treatment-emergent dyskinesia as defined with AIMS (score ⩾3 on any one item post baseline or scores ⩾2 on any two items post baseline among patients without either criterion at baseline), whereas five (0.8%) patients met criteria for AIMS-defined treatment-emergent dyskinesia during SPIII. However, no patients reported any spontaneous AEs of dyskinesia during SPIII. During SPII, 10.0% of patients used benzodiazepines and 1.9% used anticholinergic drugs, whereas in SPIII, 9.1% of patients used benzodiazepines and 1.4% used anticholinergic drugs.

During the open-label phases of the study, a significant mean increase from baseline to last visit was observed for weight (4.15 kg; *p*\<0.001). Mean changes from baseline to last visit in fasting metabolic parameters of glucose (0.0 mmol/l), cholesterol (0.01 mmol/l), low-density lipoprotein (LDL) cholesterol (0.0 mmol/l), high-density lipoprotein (HDL) cholesterol (−0.05 mmol/l), and triglycerides (0.12 mmol/l) were not statistically significant (*p*-values⩾0.313).

With regard to weight gain, 34.8% of patients\' weight increased by ⩾7% from their baseline, 6.2% increased by ⩾15%, and 1.1% increased by ⩾25%. Normal to high categorical changes were observed for fasting glucose in 6.6% of patients, cholesterol in 9.4%, LDL cholesterol in 3.0%, and triglycerides in 22.6%, and 24.9% of patients had changes from normal to low HDL cholesterol.

Relapse-Prevention Phase (SPIV)
-------------------------------

No treatment group differences were observed in any demographic or baseline clinical/psychiatric characteristics of randomized patients ([Table 1B](#tbl1B){ref-type="table"}).

Of the 444 (49.8%) patients that met stabilization criteria, 221 were randomized to OFC and 223 to fluoxetine. There were 37.1% of patients in the OFC group who discontinued compared with 47.5% in the fluoxetine group (*p*=0.028). The most common reason for discontinuation was relapse criteria met (OFC, *N*=24 (10.9%) *vs* fluoxetine, *N*=63 (28.3%); *p*\<0.001; [Figure 1b](#fig1){ref-type="fig"}). Almost twice the number of OFC patients discontinued owing to AEs (OFC, *N*=19 (8.6%) *vs* fluoxetine, *N*=10 (4.5%); *p*=0.061).

### Efficacy

A Kaplan--Meier plot of time-to-relapse, using the primary definition of relapse, is presented in [Figure 2](#fig2){ref-type="fig"}. OFC-treated patients showed a significantly longer time-to-relapse (*p*\<0.001) than did fluoxetine-treated patients. Time-to-relapse analyzed by each of the individual criteria was consistent with the primary definition, with the exception of hospitalizations, which were too few to generate a strong test. Relapse rates were lower for OFC *vs* fluoxetine (primary definition: 15.8% *vs* 31.8% of patients; scale-based definition: 14.0% *vs* 28.3% of patients; and discontinuation-based definition: 10.9% *vs* 28.3% of patients; each test yielded *p*\<0.001). Following the observed results of the Kaplan--Meier analysis, a Cox proportional hazards analysis under the primary relapse definition generated a hazard ratio of 2.37 (fluoxetine:OFC) and 95% confidence interval (1.58, 3.55), indicating that the hazard of relapse for the fluoxetine group was approximately twice that of the OFC group.

During SPIV, there was no difference between groups in incidence of patients who met response at any time after randomization (OFC *n*=215 (97.3%), fluoxetine *n*=210 (94.2%)) (*p*=0.126). More OFC-treated patients (*n*=191 (86.4%)) compared with fluoxetine-treated patients (*n*=176 (78.9%)) met the remission definition at any time (*p*=0.047) and at endpoint (*n*=136 (61.5%) *vs n*=112 (50.2%); *p*=0.011).

For OFC-treated patients, mean total MADRS score increased from 5.36 at baseline to 8.07 at endpoint (least squares (LS) mean change, 3.0) compared with an increase from 5.40 at baseline to 11.82 at endpoint (LS mean change, 6.8) (*p*\<0.001) for fluoxetine-treated patients. Similar mean changes in favor of OFC were observed from baseline to endpoint CGI-S scores (*p*=0.002).

The mean change in Sheehan Disability Scale global functional impairment total score from baseline was greater in fluoxetine-treated patients than in OFC-treated patients at endpoint (LS mean change: fluoxetine, 3.24; OFC, 1.30; *p*=0.007), indicating less worsening in functional impairment in OFC-treated patients during SPIV. A difference was also observed for the three subscores.

Results from the Resource Utilization Questionnaire evaluation revealed that the majority of patients taking fluoxetine and OFC were living either independently (29.3% and 34.5%, respectively) or with family members (69.8% and 63.3%, respectively) at endpoint. Patients taking fluoxetine and OFC, 52.6% and 49.6%, respectively, were working for pay, with 2.6% unemployed owing to depression and 19.0% unemployed unrelated to depression for patients taking fluoxetine, and 7.2% unemployed owing to depression and 16.5% unemployed unrelated to depression for patients taking OFC.

### Safety

There was one death during the study (in SPIV). A 50-year-old male, randomly assigned to ongoing OFC treatment, was admitted at the intensive care unit for hemoptysis and was diagnosed with widely spread metastatic cancer, primary believed to be lung, but unknown. The subject had a history of 30+ years of smoking and chronic obstructive pulmonary disease, and death was judged by the investigator as unrelated to study medication.

No significant differences between treatment groups were observed in occurrence of SAEs (*p*=0.621). Sixteen patients (OFC, *n*=9 (4.1%) *vs* fluoxetine, *n*=7 (3.1%)) reported ⩾1 SAE during SPIV. The most frequently occurring SAE and the only event reported in \>1 patient in both treatment groups was depression (OFC, three (1.4%); fluoxetine, three (1.3%)). TEAEs were reported in 105 (47.5%) OFC-treated patients and 111 (49.8%) fluoxetine-treated patients, with no significant difference between treatment groups (*p*=0.636, [Table 2](#tbl2){ref-type="table"}). Twice as many OFC-treated patients discontinued owing to an AE with weight increase being most common (*n*=6 (2.7%)). The most frequent reasons for discontinuation owing to an AE in fluoxetine-treated patients were increased weight (*n*=2 (0.9%)) and anxiety (*n*=2 (0.9%)). There were no TEAEs occurring at a frequency ⩾10%. No OFC-treated patients and one fluoxetine-treated patient (0.4%) reported treatment-emergent mania. No significant differences were observed between treatments in time to discontinuation owing to AEs (*p*=0.236).

There were no significant differences in overall concomitant medication use between treatments; however, more fluoxetine-treated patients (31 (13.9%)) concomitantly used ⩾1 benzodiazepine or anticholinergic medication compared with OFC-treated patients (15 (6.8%); *p*=0.008). A total of 6.3% of OFC-treated patients used benzodiazepines compared with 12.6% of fluoxetine-treated patients. Additionally, 0.5% of OFC-treated patients used anticholinergic drugs, whereas 1.8% of fluoxetine-treated patients used anticholinergic drugs during SPIV.

Two (0.9%) OFC-treated patients and two (0.9%) fluoxetine-treated patients experienced treatment-emergent akathisia (*p*=1.000). Three (1.4%) OFC-treated patients experienced treatment-emergent Parkinsonism compared with no fluoxetine-treated patients (*p*=0.248). One OFC-treated patient (0.5%) and no fluoxetine-treated patients reported dyskinesia (*p*=1.000). During SPIV, 4.1% (*n*=9) of OFC-treated patients reported suicidal ideation based on C-SSRS compared with 6.3% (*n*=14) of fluoxetine-treated patients (*p*=0.392). No patients exhibited suicidal behaviors. Suicide-related behavior and ideation assessed by C-SSRS demonstrated no differences between OFC and fluoxetine treatments (*p*\>0.274). There were no significant differences between treatment groups in the incidence of suicide-related behavior and ideation with no reports of suicidal acts.

Weight and metabolic categorical and mean changes from baseline are presented in [Tables 3A](#tbl3A){ref-type="table"} and [3B](#tbl3B){ref-type="table"}. There were significant differences in the percentage of patients who experienced clinically significant (⩾7%) weight loss (OFC: 5.0%, fluoxetine: 15.3% *p*\<0.001) and weight gain (OFC: 11.8%, fluoxetine: 2.3% *p*\<0.001). At endpoint, mean differences were significant for weight (OFC: 1.14 kg, fluoxetine: −2.78 kg; *p*\<0.001). In general, categorical and mean glucose, triglyceride, and cholesterol changes (decreases in HDL) were greater in OFC-treated patients. More OFC-treated patients experienced categorical high prolactin values compared with fluoxetine-treated patients (14.9% *vs* 6.3% respectively, *p*=0.009).

At endpoint, differences were observed for standing diastolic blood pressure (OFC: −0.21 mm Hg, fluoxetine: −1.74 mm Hg; *p*=0.044). There were no significant treatment group differences in mean changes from baseline in electrocardiographic intervals and heart rate. The only changes noted within treatment groups were for OFC-treated patients in QRS interval (LS mean change, 1.50 ms; *p*=0.022), and QTcF interval (LS mean change, −3.12 ms; *p*=0.036), and QTcR interval regression correction (LS mean change, −3.11 ms; *p*=0.043). The risk of induction of mania was low for the full duration of the study in both treatment groups with only a single mania-related event reported for fluoxetine treatment.

DISCUSSION
==========

Adjunctive therapy with SGAs has proven useful for patients who have had an inadequate response to antidepressant medications in patients with TRD ([@bib12]; [@bib19]). The combination of olanzapine and fluoxetine has similarly been shown to be an effective treatment for patients with TRD ([@bib36]; [@bib39]). Nevertheless, the question remains regarding how long to continue the adjunctive SGA when the strategy has been effective. Although one might assume that both the SGA and the antidepressant may need to be continued, to date the only relevant study conducted in a TRD patients reported a lack of additional benefit beyond short-term treatment with risperidone augmentation of citalopram therapy ([@bib32]).

Our study, thus, was designed to answer this important clinical question, and the primary objective of the study was met as patients treated with OFC *vs* fluoxetine experienced longer times to relapse. Also, OFC-treated subjects demonstrated higher remission rates and lower relapse rates. Response rates were not different between the two treatments; a likely result of various factors such as subjects having already received open-label acute and stabilization treatment benefits of OFC for ⩽20 weeks, the fact that response was required for patients entering SPIV (a threshold easily reached or maintained during this study phase), and finally, that fluoxetine is an established effective antidepressant. Although both groups experienced mean increases in MADRS during the double-blind period, changes were smaller for OFC than for fluoxetine. This may have clinical relevance as the mean MADRS at 27 weeks for OFC-treated patients was within the remission threshold of ⩽8 but above the remission threshold for the fluoxetine group (11.8), consistent with findings of greater likelihood of remission at endpoint with OFC treatment. The risks associated with a lack of remission during treatment or a higher likelihood of relapse with treatment include suicide, increased treatment costs, poorer outcomes, and greater morbidity ([@bib25]). Although, in this study, we found no differences in frequency of suicidal ideation and behaviors rated by the C-SSRS and, at best, inconsistent functional benefits between the two treatments; however, the Sheehan disability scale suggests lesser worsening in functional impairment with OFC. Previous studies of OFC in TRD have been of short-term duration ([@bib14]; [@bib35], [@bib36]; [@bib39]; [@bib42]); however, the present results provide data that support the potential use of OFC in long-term TRD treatment.

This study has several pragmatic aspects of clinical relevance. First, it mimics real-life clinical practice, such as when an antipsychotic combined with an antidepressant for TRD treatment is being considered for discontinuation. When this occurs, it is likely that the same antidepressant will be continued; hence, the study provides clinically relevant information regarding long-term treatment choices for patients with TRD acutely treated and stabilized with OFC. Second, it begins to address a common and important clinical conundrum related to the adjunctive use of antipsychotics in a (resistant) depressed population, and the well-known short- and long-term risks of SGAs (especially weight and metabolic changes). So, despite the clinically relevant and important efficacy and potential functional findings in this study of continued OFC treatment compared with fluoxetine as reported above, the clinician must weigh these benefits against the possible added risks of keeping the patient on a SGA, particularly the risks of weight gain and other metabolic changes. This study may not answer all of these questions, but the incidence of SAEs and TEAEs in this study were not different between treatments during the relapse-prevention phase. This may well be due to a certain degree of tolerance already developed with ⩽20 weeks of open-label OFC treatment. This tolerance or prior exposure may also explain the absence of EPS (Parkinson\'s, Akathisia, or Tardive Dyskinesia) and prolactin differences between the two treatments. However, twice as many patients randomized to OFC discontinued owing to an AE, weight gain being the most common reason, and patients generally had greater significant mean increases and greater categorical changes in weight, glucose, triglycerides, and HDL cholesterol. These metabolic findings are consistent with previous analyses of long-term weight and metabolic changes in adults treated with olanzapine or OFC ([@bib23]; [@bib38]; [@bib46]). To provide additional perspective about the potential for longer-term weight changes with OFC, [@bib3] published a 76-week open-label analysis on weight gain in subjects with MDD (26% with TRD) and reported a similar percentage of subjects who gained ⩾7% of their baseline weight (56%); a Kaplan--Meier curve of time to ⩾7% gain seems to plateau after 40 weeks of treatment; and the median time to ⩾7% weight gain was 16 weeks, which could partially explain the apparent lack of difference in clinically significant weight gain after 47 and 76 weeks of treatment.

Some limitations to this study should be considered. The study may have had better signal detection if it had used at least one prospective treatment trial to establish the required history of TRD. However, this design feature would have increased the duration of the study and increased discontinuation rates. We note that the retrospective approach used in the study is consistent with the definition (and identification) of patients with TRD for which OFC is indicated as short-term therapy ([@bib38]). Further, the study design incorporated a blinded olanzapine taper to prevent the possibility of unblinding due to rapid discontinuation of olanzapine during SPIV. Another limitation is that fluoxetine was the only antidepressant used as a comparator. We recognize that the use of olanzapine in combination with other currently available antidepressants, some with a different mechanism of action, would have broadened the generalizability of the findings. Last, as a relapse-prevention study may be viewed as an example of an enriched design (ie, all randomized patients had both tolerated and responded to therapy with OFC), our results may not be generalizable to patients who do not respond to OFC or who have not had prior exposure to OFC.

Continued maintenance with OFC treatment rather than switching to fluoxetine therapy after stabilization on OFC was significantly superior in time-to-relapse and risk-of-relapse in the long-term treatment of TRD. The safety findings during long-term OFC treatment in this study were consistent with OFC\'s known safety profile ([@bib13]; [@bib39]; [@bib42]; [@bib38]). The decision to continue treatment with OFC or fluoxetine must be based on individual patient needs and balanced against the potential for metabolic changes that may occur with long-term OFC treatment. Although continued treatment with fluoxetine alone may still be a valid treatment option for some patients, shorter time-to-relapse, significantly higher relapse rates, and lower remission rates observed with fluoxetine in this study must also be considered.
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![(a) Study design. *N/n*, number of patients; OFC, olanzapine and fluoxetine hydrochloride combination; SP, study period; V, visit; W, week. (b) Patient disposition. ^a^Patients moved into the stabilization study period after at least 6 weeks of treatment (at visits 8 or 9) if they met response criteria. The patient\'s next visit after the move was in SPIII at visit 11. Patients who did not meet response criteria by visit 10 were discontinued from the study. ^b^Dose changes were not allowed after visit 19. ^c^Patients who did not meet stabilization criteria were discontinued from the study. ^d^The week number designations used in this figure represent the maximum number of weeks according to the overall trial design, and not the duration of treatment for each patient.](npp2014101f1){#fig1}

![Time-to-relapse (primary definition). Patients who have not met relapse criteria are considered as censored at the time of discontinuation. Log-rank test was used for treatment group comparison (*p*\<0.001). FLU, fluoxetine; OFC, olanzapine and fluoxetine hydrochloride combination.](npp2014101f2){#fig2}

###### Baseline Patient Demographics and Clinical Characteristics of Patients (Study Periods II and III)

  **Characteristic**                                                    **SPII** **OFC, *N*=892**   **SPIII** **OFC, *N*=655**
  --------------------------------------------------------------------- --------------------------- ----------------------------
  Age (years), mean (SD)                                                44.4 (12.0)                 44.4 (12.0)
                                                                                                     
  *Gender, n (%)*                                                                                   
   Male                                                                 301 (33.7)                  212 (32.4)
   Female                                                               591 (66.3)                  443 (67.6)
                                                                                                     
  *Race, n (%)*                                                                                     
   Caucasian                                                            634 (71.1)                  470 (71.8)
   Other                                                                255 (28.9)                  183 (28.2)
                                                                                                     
   Body weight (kg), mean (SD)                                          80.4 (21.6)                 82.5 (22.0)
   Height (cm), mean (SD)                                               166.0 (9.6)                 165.4 (9.4)
   BMI (kg/m^2^), mean (SD)                                             29.1 (7.4)                  30.1 (7.3)
   Age at first episode (years), mean (SD)                              30.8 (12.8)                 31.0 (12.9)
   Age at current episode (years), mean (SD)                            42.2 (12.2)                 42.4 (12.3)
   Number of previous episodes[a](#t1A-fn1){ref-type="fn"}, mean (SD)   4.3 (9.8)                   3.9 (7.5)
   Duration of current episode (days),  mean (SD)                       651.1 (1155.6)              640.6 (1167.0)
   MADRS total score (SD)                                               30.4 (5.3)                  9.3 (4.4)
   CGI-S score (SD)                                                     4.6 (0.7)                   2.3 (0.8)

Abbreviations: BMI, body mass index; CGI-S, Clinical Global Impressions-Severity of Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; *N*, number of patients involved in the summary; *n*, number of patients in the given category; OFC, olanzapine and fluoxetine hydrochloride combination; SD, standard deviation; SP, study period.

Does not include current episode.

###### Baseline Patient Demographics and Clinical Characteristics of Patients (Study Period IV)

  **Characteristic**                                                    **SPIV** **OFC, *N*=221**   **SPIV** **FLU, *N*=223**              ***p*-value**
  --------------------------------------------------------------------- --------------------------- --------------------------- -----------------------------------
  Age (years), mean (SD)                                                44.9 (11.8)                 44.1 (12.3)                  0.404[a](#t1B-fn1){ref-type="fn"}
  *Gender, n (%)*                                                                                                                0.378[b](#t1B-fn2){ref-type="fn"}
   Male                                                                 78 (35.3)                   70 (31.4)                                     
   Female                                                               143 (64.7)                  153 (68.6)                                    
                                                                                                                                                  
  *Race, n (%)*                                                                                                                 
   Caucasian                                                            156 (70.6)                  158 (70.9)                                    
   Other                                                                63 (28.6)                   65 (29.1)                                     
                                                                                                                                                  
   Body Weight (kg), mean (SD)                                          84.1 (22.0)                 82.2 (21.1)                  0.289[a](#t1B-fn1){ref-type="fn"}
   Height (cm), mean (SD)                                               165.8 (9.1)                 164.9 (9.5)                  0.298[a](#t1B-fn1){ref-type="fn"}
   BMI (kg/m^2^), mean (SD)                                             30.5 (6.9)                  30.2 (7.5)                   0.174[a](#t1B-fn1){ref-type="fn"}
   Age at first episode (years), mean (SD)                              31.7 (12.4)                 31.7 (13.4)                  0.963[a](#t1B-fn1){ref-type="fn"}
   Age at current episode (years), mean (SD)                            43.1 (12.2)                 42.1 (12.3)                  0.349[a](#t1B-fn1){ref-type="fn"}
   Number of previous episodes[c](#t1B-fn3){ref-type="fn"}, mean (SD)   3.5 (4.2)                   3.8 (9.7)                    0.619[a](#t1B-fn1){ref-type="fn"}
   Duration of current episode (days), mean (SD)                        546.3 (972.7)               640.2 (1171.4)               0.461[a](#t1B-fn1){ref-type="fn"}
   MADRS total score[d](#t1B-fn4){ref-type="fn"}, mean (SD)             5.4 (3.8)                   5.4 (4.0)                    0.871[a](#t1B-fn1){ref-type="fn"}
   CGI-S score^e^, mean (SD)                                            1.7 (0.7)                   1.7 (0.8)                    0.491[a](#t1B-fn1){ref-type="fn"}

Abbreviations: ANOVA, analysis of variance; BMI, body mass index; CGI-S, Clinical Global Impressions-Severity of Depression; CMH, Cochran-Mantel-Haenszel; FLU, fluoxetine; LS, least squares; MADRS, Montgomery-Åsberg Depression Rating Scale; *N*, number of patients involved in the summary; *n*, number of patients in the given category; OFC, olanzapine and fluoxetine hydrochloride combination; SD, standard deviation; SE, standard error; SP, study period.

*p*-values are from ANOVA with treatment and country as independent variables in the model.

*p*-values are from CMH test adjusting by country.

Does not include current episode.

MADRS mean change at endpoint (LS Mean (SE)): 3.0 (0.7), OFC; 6.8 (0.7), FLU; *p*\<0.001.

CGI-S mean change at endpoint (LS Mean (SE)): 0.2 (0.1), OFC; 0.5 (0.1), FLU; *p*=0.002.

###### Treatment-Emergent Adverse Events Reported in At Least 2% of Patients (Study Periods II Through IV)

  **Event, *n* (%)**                  **SPII OFC *N*=892**   **SPIII OFC *N*=655**   **SPIV OFC *N*=221**   **SPIV FLU *N*=223**
  ----------------------------------- ---------------------- ----------------------- ---------------------- ----------------------
  Patients with ⩾1 TEAE               610 (68.4)             352 (53.7)              105 (47.5)             111 (49.8)
  Weight increased                    151 (16.9)             59 (9.0)                8 (3.6)                5 (2.2)
  Dry mouth                           125 (14.0)             8 (1.2)                 0 (0.0)                1 (0.4)
  Increased appetite                  123 (13.8)             11 (1.7)                3 (1.4)                1 (0.4)
  Somnolence                          76 (8.5)               20 (3.1)                1 (0.5)                3 (1.3)
  Fatigue                             68 (7.6)               15 (2.3)                2 (0.9)                2 (0.9)
  Headache                            64 (7.2)               39 (6.0)                15 (6.8)               13 (5.8)
  Sedation                            61 (6.8)               17 (2.6)                3 (1.4)                0 (0.0)
  Nasopharyngitis                     37 (4.1)               23 (3.5)                9 (4.1)                12 (5.4)
  Nausea                              34 (3.8)               18 (2.7)                10 (4.5)               8 (3.6)
  Tremor                              33 (3.7)               10 (1.5)                1 (0.5)                2 (0.9)
  Edema peripheral                    32 (3.6)               11 (1.7)                0 (0.0)                0 (0.0)
  Dizziness                           29 (3.3)               6 (0.9)                 0 (0.0)                3 (1.3)
  Constipation                        24 (2.7)               3 (0.5)                 0 (0.0)                0 (0.0)
  Anxiety                             23 (2.6)               12 (1.8)                2 (0.9)                9 (4.0)
  Restlessness                        22 (2.5)               7 (1.1)                 1 (0.5)                0 (0.0)
  Diarrhea                            20 (2.2)               5 (0.8)                 5 (2.3)                6 (2.7)
  Insomnia                            20 (2.2)               16 (2.4)                8 (3.6)                16 (7.2)
  Upper respiratory tract infection   9 (1.0)                20 (3.1)                11 (5.0)               7 (3.1)
  Blood triglycerides increased       17 (1.9)               15 (2.3)                4 (1.8)                1 (0.4)
  Vomiting                            12 (1.3)               15 (2.3)                6 (2.7)                4 (1.8)
  Depression                          3 (0.3)                5 (0.8)                 5 (2.3)                15 (6.7)
  Gastroenteritis                     4 (0.4)                6 (0.9)                 6 (2.7)                3 (1.3)

Abbreviations: FLU, fluoxetine; OFC, olanzapine and fluoxetine hydrochloride combination; SP, study period; TEAE, treatment-emergent adverse event.

###### Weight and Metabolic Safety Treatment-Emergent Categorical Changes, Relapse-Prevention Phase

  **Parameter**[a](#t3A-fn1){ref-type="fn"}    **Abnormality direction**   **Criteria at baseline**   **Criteria at endpoint**  **OFC *n*/*N* (%)**   **FLU *n*/*N* (%)**   ***p*-value**[b](#t3A-fn2){ref-type="fn"}
  ------------------------------------------- --------------------------- -------------------------- -------------------------- --------------------- --------------------- -------------------------------------------
  Weight[c](#t3A-fn3){ref-type="fn"}                    N to L                       N/A                    Decrease ⩾7%        11/220 (5.0)          34/222 (15.3)         \<0.001
                                                        N to H                       N/A                    Increase ⩾7%        26/220 (11.8)         5/222 (2.3)           \<0.001
  Glucose (mmol/l)                                      I to H                 ⩾5.55 and \<6.99                ⩾6.99            18/98 (18.4)          7/97 (7.2)            0.031
                                                        N to H                      \<5.55                     ⩾6.99            4/90 (4.4)            5/96 (5.2)            1.000
                                                        N to I                      \<5.55                ⩾5.55 and \<6.99      32/90 (35.6)          27/96 (28.1)          0.344
  Cholesterol (mmol/l)                                  B to H                 ⩾5.18 and \<6.22                ⩾6.22            21/75 (28.0)          17/83 (20.5)          0.352
                                                        N to B                      \<6.22                ⩾5.18 and \<6.22      8/47 (17.0)           10/59 (16.9)          1.000
                                                        N to H                      \<6.22                     ⩾6.22            1/47 (2.1)            2/59 (3.4)            1.000
  LDL Cholesterol (mmol/l)                              B to H                 ⩾2.59 and \<4.14                ⩾4.14            20/115 (17.4)         14/134 (10.4)         0.139
                                                        N to B                      \<2.59                ⩾2.59 and \<4.14      5/22 (22.7)           8/26 (30.8)           0.746
                                                        N to H                      \<2.59                     ⩾4.14            1/22 (4.5)            0/26 (0.0)            0.458
  Direct HDL Cholesterol (mmol/l)                       N to L                      ⩾1.04                      \<1.04           78/199 (39.2)         53/208 (25.5)         0.004
  Triglycerides (mmol/l)                                B to EH                ⩾1.70 and \<2.26                ⩾5.65            0/47 (0.0)            0/41 (0.0)            N/A
                                                        B to H                 ⩾1.70 and \<2.26                ⩾2.26            24/47 (51.1)          11/41 (26.8)          0.029
                                                        N to B                      \<1.70                ⩾1.70 and \<2.26      15/68 (22.1)          5/74 (6.8)            0.014
                                                        N to EH                     \<1.70                     ⩾5.65            0/68 (0.0)            0/74 (0.0)            N/A
                                                        N to H                      \<1.70                     ⩾2.26            11/68 (16.2)          4/74 (5.4)            0.054

Abbreviations: B, borderline; EH, extremely high; FLU, fluoxetine; H, high; HDL, high-density lipoprotein; I, impaired; L, low; LDL-low-density lipoprotein; N, normal; *N*, number of patients involved in the summary; *n*, number of patients in the given category; N/A, not applicable; OFC, olanzapine and fluoxetine hydrochloride combination.

Changes in metabolic parameters were measured in a fasting state.

*p*-values from Fisher\'s exact test.

Refers to change in weight for patients during the relapse-prevention phase who were normal at baseline.

###### Mean Change from Baseline in Weight and Metabolic Safety Parameters, Relapse-Prevention Phase

  **Parameter**[a](#t3B-fn1){ref-type="fn"}    **Therapy**  **Baseline**   **Change from baseline**   ***p*-value**[b](#t3B-fn2){ref-type="fn"}                        
  ------------------------------------------- ------------- -------------- -------------------------- ------------------------------------------- ----- ------- ------ ---------
  Weight (kg)                                      OFC      220            84.3                       22.0                                        140   1.14    0.33   \<0.001
                                                   FLU      222            82.2                       21.1                                        117   −2.78   0.36    
  Glucose (mmol/l)                                 OFC      200            5.38                       1.05                                        130   0.20    0.08   0.002
                                                   FLU      198            5.38                       1.25                                        110   −0.12   0.08    
  Cholesterol (mmol/l)                             OFC      212            5.46                       1.11                                        137   −0.07   0.08   0.839
                                                   FLU      209            5.33                       1.02                                        117   −0.04   0.09    
  LDL Cholesterol (mmol/l)                         OFC      200            3.26                       0.95                                        135   −0.02   0.08   0.703
                                                   FLU      203            3.13                       0.89                                        116   0.02    0.08    
  Direct HDL Cholesterol (mmol/l)                  OFC      211            1.36                       0.45                                        137   −0.04   0.02   0.001
                                                   FLU      207            1.40                       0.47                                        117   0.05    0.02    
  Triglycerides (mmol/l)                           OFC      211            1.94                       1.21                                        137   −0.09   0.06   0.083
                                                   FLU      209            1.77                       0.91                                        117   −0.24   0.07    

Abbreviations: FLU, fluoxetine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LS, least squares; *N*, number of patients involved in the summary; OFC, olanzapine and fluoxetine hydrochloride combination; SD, standard deviation; SE, standard error.

Changes in metabolic parameters were measured in a fasting state.

*p*-values from *t*-test of between group LS Mean difference.
